Nuvalent: Targeted Oncology Biotech and GSK Acquisition

Nuvalent is a precision-oncology biotech company that uses structure-based drug design to create small-molecule therapies aimed at specific genetic drivers of cancer. Its pipeline is focused primarily on non-small cell lung cancer (NSCLC), with additional discovery programs in progress. Source 1

Core Pipeline

The company’s lead programs target ROS1-positive NSCLC with brain-penetrant inhibitors currently under FDA review. A next-generation ALK inhibitor is designed to overcome resistance mutations in previously treated patients, while an investigational therapy addresses HER2 mutations and amplifications, expanding Nuvalent’s reach across molecularly defined lung cancers. Source 5

GSK Acquisition Details

In June 2026, GSK announced it would acquire Nuvalent for $10.6 billion, marking the company’s largest deal in over a decade and its second-largest transaction ever. The agreement represents the first major move under new CEO Luke Miels. Source 4

Strategic Rationale and Outlook

The acquisition bolsters GSK’s oncology portfolio ahead of anticipated revenue declines and adds three late-stage lung-cancer assets with near-term regulatory catalysts. Integration is expected to accelerate global development and commercialization, strengthening GSK’s position in precision lung-cancer therapies. Source 2